JLPC(SH:600513) Zheng Quan Zhi Xing·2025-09-04 16:06Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Amlodipine Besylate Tablets from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][2]. Drug Registration Details - The drug registered is Amlodipine Besylate Tablets, available in dosages of 5mg and 10mg, classified as a chemical drug of category 4, and is a prescription medication [1][2]. - The sales revenue for Amlodipine Besylate Tablets in hospitals across China reached 1.216 billion yuan in 2024 [2]. R&D Investment and Production - As of the announcement date, the R&D investment for Amlodipine Besylate Tablets by Changle Pharmaceutical is approximately 3.83 million yuan (unaudited) [2]. - Changle Pharmaceutical has obtained four production licenses for the drug as of the announcement date [2]. Impact on the Company - The acquisition of the Drug Registration Certificate is expected to enrich the product line of the company and its subsidiaries, thereby enhancing their market competitiveness [2]. - The impact on the company's recent operating performance is not expected to be significant [2].